Author (Corporate) | European Medicines Agency |
---|---|
Series Title | Press Release |
Series Details | EMA/CHMP/675745/2012 (19.10.12) |
Publication Date | 19/10/2012 |
Content Type | News |
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), in October 2012, made a recommendation to give marketing authorisation to insulin degludec, a new basal analogue insulin for the treatment of diabetes mellitus in adults. It is introduced in a pre-filled pen in two formulations – 100 units/ml and 200 units/ml. This is the first insulin approved in Europe at a higher strength than the EU-wide standard of 100 units/ml, for many years the only strength of insulin available across the EU. It will be marketed under the trade name Tresiba. |
|
Source Link | Link to Main Source http://www.emea.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/10/news_detail_001638.jsp&mid=WC0b01ac058004d5c1 |
Related Links |
|
Subject Categories | Health |
Countries / Regions | Europe |